Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
As the list of known mutations and relevant genes for lymphoid disorders increases, characterizing these samples becomes more complicated and time-consuming. To get meaningful genetic insights, you need a rapid and efficient approach for evaluating all key mutations upfront. Next-generation sequencing (NGS) can streamline the path from sample to result by providing a comprehensive molecular profile with speed and simplicity.
NGS has become a key component of molecular testing in both myeloid and lymphoproliferative neoplasms. It can facilitate improvements in classification, prognostication and identification of therapeutic targets. In this presentation, hear our expert share the utility of faster molecular results in lymphoid genomic profiling and their experience with the Genexus System and the Ion AmpliSeq Liverpool Lymphoid Network Panel.
In this on-demand webinar, Dr. Gerard Frigola discusses his experience with the new Ion AmpliSeq Liverpool Lymphoid Network Panel and shares compelling analytical data from his lab to demonstrate the impact of NGS for lymphoid
malignancy research.
The Ion AmpliSeq Liverpool Lymphoid Network Panel is a community panel designed by leading clinical researchers for more comprehensive lymphoid genomic profiling.
Rapid | Automated | Comprehensive | Verified performance | Community network |
Go from specimen to result in as little as one day | Process samples with minimal hands-on time, available on both GeneStudio & Genexus | Simultaneously profile 60 key DNA mutations relevant for a broad range of lymphoid disorders | Reliably detect variants using a panel designed and tested by community users with real-world clinical research samples | Access a community network of labs and contribute to future iterations of the panel design |
Panel content has been curated to cover relevant targets for T-cell and B-cell lymphomas, leukemias and other lymphoproliferative disorders. It is compatible with all common sample types, including blood, bone marrow and formalin-fixed paraffin embedded (FFPE) tissue.
Ion AmpliSeq panel design includes:
Essential exons (36) | Full coding sequence (24) | ||
BCL6 | IRF4 | ARID1A | PAX5 |
BIRC3 | KRAS | ATM | PIM1 |
BRAF | MAP2K1 | B2M | PRDM1 |
BTK | MYD88 | BCL2 | PTEN |
CARD11 | NOTCH1 | CDKN2A | SAMHD1 |
CCND1 | NOTCH2 | CREBBP | SGK1 |
CCND3 | NRAS | DIS3 | SOCS1 |
CD79B | PLCG2 | GNA13 | TENT5C |
CXCR4 | POT1 | ID3 | TET2 |
DNMT3A | RHOA | KMT2D | TNFAIP3 |
EP300 | RPS15 | MEF2B | TP53 |
ETV6 | SF3B1 | MYC | |
EZH2 | SMARCA4 | NFKBIE | |
FAS | STAT3 | ||
FBXW7 | STAT5B | ||
FOXO1 | STAT6 | ||
HRAS | TNFRSF14 | ||
IDH2 | XPO1 |
The Oncomine Lymphoma Panel contains 25 key genes associated with all major B-cell lymphomas, including DLBCL, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphomas. This panel provides robust performance with as little as 10 ng of input and comes with an end-to-end, clinical research-grade workflow including straightforward, customizable report that summarizes the findings. It is available for the Ion Chef and Ion GeneStudio S5 systems. Customize the assay to suit your needs by selecting from a library of primer designs to add additional gene targets.
Lymphoma | |||||
ARID1A | BRAF | CDKN2A | HIST1H1E | MYD88 | TNFAIP3 |
ATM | BTK | CREBBP | KMT2D | PIM1 | TNFRSF14 |
B2M | CARD11 | EZH2 | MTOR | SOCS1 | TP53 |
BCL2 | CD79B | GNA13 | MYC | SF3B1 | XPO1 |
BCL6 |
The Oncomine Comprehensive Assay v3 is available on the Genexus System and additionally available for use on the Ion GeneStudio S5 System with manual or automated library preparations.
We will be happy to answer your questions and provide a demo of our NGS solutions.
For Research Use Only. Not for use in diagnostic procedures.